short-right-arrow logoMobile media-pie 1 7 % share download email linkedin round-download

Privacy Preference Centre

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. We use two types of cookies on our website: cookies which are necessary for this website to function and analytics cookies. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies used

  • CookieNotice
  • CookieAnalytics


Analytics Cookies

These are Google Analytics cookies which allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site and social media platforms All information these cookies collect is aggregated and therefore anonymous. This cookie is defaulted to ‘Active’, which means we will be able to track, on any anonymous basis, how many visitors we have to our site, and monitor its performance. If you wish to turn them off you can do so by unticking ‘Active’ and clicking ‘Save and Accept Cookies’. For more information on how these cookies work, including a link through to the Google Privacy Policy which sets out further information about data which Google may collect in the course of providing us with Analytics.

Cookies used

  • _ga

Targeting Cookies

We use necessary cookies to make our site work. We also use analytics cookies which collect information about how visitors use our website and help us to improve it; these are defaulted to ‘Active’, if you wish to turn them off you can do so through the Cookie Settings. Please be aware that by blocking some types of cookies it may impact your experience of the site and the services we are able to offer. For more information about any of these cookies and our use of them, or to change your settings at any time, please see Cookie Settings and our Cookies Policy.

Bridgepoint in the News

05 July 2021

Bridgepoint Growth to partner with PharmaReview

PharmaReview, a UK provider of compliance and copy review services for promotional materials used in the life sciences sector, has partnered with Bridgepoint Growth to further support the growth of the business. Terms of the transaction are confidential.

Established in 2011 to solve the problem of inefficient medical review processes in pharma companies, the company is a supplier to some of the world’s largest pharma groups, ensuring that the latter’s promotional materials are medically accurate, make scientific sense, comply with ethical legal and regulatory code requirements, and ensure all claims are backed up with references to accurate and up-to-date underlying sources.

This outsourced service reduces the time it takes for pharma groups to get materials through the review process, providing certainty to clients regarding when they will receive quality-controlled documents for amendment or final approval and release into the market.

Ralph Carter, co-founder and director of PharmaReview, said: “It has taken a long time, but thanks to our young and energetic team, and feedback from our clients while we protoyped the service, I'm delighted that we have solved a significant source of inefficiency in the pharma industry. PharmaReview is now a successful and growing business, and we need help with that growth. Bridgepoint bring depth of experience in expansion and will work with us to help us realise our potential. For our existing clients in life sciences, we will continue to offer world class compliance and copy review, and this will give us the opportunity to roll out to the rest of the industry.

Commenting on the transaction, PharmaReview co-founder and director Tessa Pugh, said: “We have reached an inflection point in our business development where the market opportunity for our services is growing quickly and we recognise the benefit of a partner who shares our growth ambitions and can work with us and provide the additional firepower to take the business to the next stage. I’m delighted to welcome Bridgepoint Growth as that new partner.”

Mayank Kanga, a director at Bridgepoint Growth said: “We believe there is a significant opportunity to broaden service offering, either through geographic or service expansion and to invest in the team to allow it to add further value to their clients and to realise the market opportunity open to them.”

Previous and current investments made by Bridgepoint in the sector include Quotient Clinical, a provider of outsourced, early-stage drug development services to the global pharmaceutical and biotechnology industries, Prescient Healthcare, a provider of decision support and advisory services for pharma clients, Fishawack Health, a provider of outsourced pharmaceutical consulting services to pharmaceutical and biotech groups globally and Phlexglobal, Phlexglobal, a specialist provider of technology-enabled document management solutions and other support services to the global clinical research market.

Advisers involved in the transaction included: for Bridgepoint – Burness Paull (Legal), Candesic (Commercial), KPMG (Financial), BDO (Tax), Lockton (Insurance); for PharmaReview – Azets and K&L Gates.

The investment was made by Bridgepoint Growth I, a fund that makes growth capital investments, typically in businesses with significant UK or Nordic operations seeking equity investment between €5 million and €20 million.

Close

Contact us

If you are interested in working for Bridgepoint, please complete the form below.

Close

Investor reports registration

To access investor reports through the web based reporting facility, please fill in the form to register for an account.

The information submitted on this form will be used for the sole purpose of registering you as an account user and will not be shared with third parties.

Close

Request a copy of The Point

Mandatory fields are marked as (required*)